For years, Washington’s diagnostic policy debate has revolved around reimbursement: who gets paid, how much, and under what coding framework. More recently, though, that conversation has started to expand. Lab testing has long been fertile ground for fraud, but as diagnostics become more technologically complex and financially significant, policymakers are again confronting how to keep oversight from falling behind innovation.
Fraud, waste, and abuse has long been a reliable talking point in federal health policy – and a more pointed one since the beginning of President Trump’s second term – but the tone is increasingly operational. President Trump highlighted program integrity efforts during his State of the Union address, which CMS quickly followed with a sweeping Request for Information tied to its new CRUSH initiative aimed at, ahem, CRUSHING fraud across Medicare and Medicaid. The agency is specifically asking stakeholders how to better detect abuse in molecular and genetic testing, including how programs like MolDX function as guardrails.
That focus isn’t theoretical. A federal jury in Texas this week convicted a laboratory owner in a $328 million Medicare genetic testing fraud scheme, another reminder that diagnostic innovation and payment complexity create fertile ground for abuse. Precision medicine may be the future of healthcare, but precision billing has clearly become a profitable side business for a few bad actors.
None of this is new. The lab sector has seen multiple waves of fraud schemes over the years—from clinical chemistry kickbacks to toxicology billing explosions and, more recently, genetic testing mills. What’s changing now is the scale and sophistication of the diagnostics entering the system. With that, the potential for misuse and overuse, intentional or otherwise, correspondingly expands.
Even the most closely watched diagnostics are facing tougher scrutiny. GRAIL’s Galleri multi-cancer early detection test failed to meet its primary endpoint in a large NHS trial, raising fresh questions about how quickly emerging screening tools should move from scientific promise to widespread adoption.
And that’s exactly the challenge. Advanced diagnostics bring new billing codes, new algorithms, and new utilization patterns that are difficult to monitor in real time. In a system historically built around retrospective enforcement, regulators often find themselves chasing problems after the money has already moved.
CMS appears increasingly determined to close that gap. The agency says it has already saved billions using AI tools to flag suspicious billing patterns, and its latest RFI asks stakeholders how machine learning and advanced analytics could expand those capabilities further.
None of this reflects skepticism about diagnostics. If anything, the opposite is true. Diagnostics is rapidly becoming the operating system for modern medicine — guiding treatment decisions, determining eligibility for high-cost therapies, and shaping the flow of billions in healthcare spending.
But the more central diagnostics become, the more the system must answer a difficult governance question: how do you encourage innovation without creating a payment environment that rewards opportunism?
Precision medicine works best when diagnostics are precise. The oversight probably should be as well.
Key Developments
CMS launches CRUSH initiative targeting diagnostic fraud
CMS issued a Request for Information seeking input on how to strengthen fraud detection across federal health programs, with particular focus on molecular and genetic diagnostic testing and the oversight role of programs such as MolDX.
$328M genetic testing fraud scheme ends in conviction
A federal jury convicted a laboratory owner in a large Medicare kickback scheme involving medically unnecessary genetic testing, underscoring persistent program integrity vulnerabilities tied to high-value diagnostics.
Galleri multi-cancer early detection trial misses primary endpoint
GRAIL reported that its Galleri blood test failed to demonstrate a statistically significant reduction in late-stage cancer diagnoses in a large NHS trial, raising new questions about the pace of MCED adoption and future reimbursement pathways.
Strategic Takeaway
Diagnostics continues to move toward the center of healthcare decision-making — powering precision therapies, earlier detection, and increasingly personalized treatment pathways. That influence inevitably attracts scrutiny.
The next phase of policy debate will not be about whether advanced diagnostics belong in the system. That question has largely been settled. The challenge now is determining how they are used, how often they are used, and how the payment system distinguishes legitimate clinical value from opportunistic utilization.
For health plans, that makes diagnostic governance a core competency. As innovation accelerates and federal policy experiments with new oversight tools, the organizations best positioned for the next phase of healthcare will be the ones that know how to translate diagnostic insight into disciplined clinical and utilization frameworks.
